VITROX ApS
CVRCVR number10034817Opløst
Company financials
Key figures
Updated 8 Aug 2022
- Return on assets
- –
- Return on equity
- 103.7%
- Current ratio
- 0%
- Equity ratio
- 73.9%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -6,465 |
Finance expenses | 22 |
Tax expense | 0 |
Profit/loss for the year | 695,915 |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 0 |
Current assets | 0 |
Non-current assets | 907,752 |
Total assets | 907,752 |
Equity | 670,988 |
Liabilities | 236,764 |
Current liabilities | 236,764 |
Working capital
| Reporting period | |
|---|---|
Trade payables | 5,000 |
Other current payables | 0 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 150,000 |
Retained earnings | 520,988 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 907,752 |
Annual report highlights
Official annual report · 2021Open official report
Business and development
Primary activities
Selskabets formål er videreudvikling af og udtagning af patenter samt forsknings- og udviklingsvirksomhed inden for bioteknologi og andre områder.
Development in activities and financial affairs
Selskabets resultatopgørelse for 2021 udviser et overskud på kr. 695.915, og selskabets balance pr. 31. december 2021 udviser en egenkapital på kr. 670.988.
Commitments and security
Contingent liabilities
Selskabet er som administrationsselskab sambeskattet med øvrige danske tilknyttede virksomheder, og hæfter solidarisk med øvrige sambeskattede selskaber for betaling af selskabsskat samt for kildeskat på udbytter, renter og royalties.
Create a free account to see up to 9 years of financial history
Create free account